Get the Stockscreener App
71.53
3.29%
-2.43
After Hours:
72.95
1.42
+1.99%
Corcept Therapeutics Inc stock is traded at $71.53, with a volume of 1.17M.
It is down -3.29% in the last 24 hours and down -1.84% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
See More
Previous Close:
$73.96
Open:
$75.17
24h Volume:
1.17M
Relative Volume:
1.40
Market Cap:
$7.54B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
56.77
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
-20.39%
1M Performance:
-1.84%
6M Performance:
+4.24%
1Y Performance:
+57.45%
1-Day Range:
$70.64
$76.84
1-Week Range:
$70.64
$91.00
52-Week Range:
$42.01
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
71.53 | 7.79B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Is Corcept Therapeutics Incorporated stock positioned well for digital economyEarnings Summary Report & Weekly Market Pulse Updates - newser.com
What moving averages say about Corcept Therapeutics Incorporated2025 Biggest Moves & AI Powered Buy and Sell Recommendations - newser.com
Technical analysis overview for Corcept Therapeutics Incorporated stockPortfolio Growth Summary & High Accuracy Trade Alerts - newser.com
How Corcept Therapeutics Incorporated stock compares to growth peers2025 Year in Review & Stock Portfolio Risk Control - newser.com
Momentum divergence signals in Corcept Therapeutics Incorporated chart2025 Retail Activity & AI Driven Price Forecasts - newser.com
How sentiment analysis helps forecast Corcept Therapeutics IncorporatedJuly 2025 Trends & Stepwise Trade Signal Guides - newser.com
Corcept Therapeutics (CORT) Is Down 16.1% After Distribution Shift and Insider Selling—What's Changed - Yahoo Finance
Maryland State Retirement & Pension System Has $2.37 Million Stock Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Insider William Guyer Sells 20,000 Shares - MarketBeat
Corcept Therapeutics (CORT) Sees Significant Drop of 13.3% - GuruFocus
Why Corcept (CORT) Shares Are Falling Today - The Globe and Mail
Corcept Therapeutics (CORT) Shares Drop as Optime Care Ends Dist - GuruFocus
Corcept Therapeutics (CORT) Adjusts Korlym Distribution Strategy - GuruFocus
Corcept Therapeutics (CORT) Shares Drop Amid Market Activity - GuruFocus
Analyzing Corcept Therapeutics Incorporated with risk reward ratio chartsQuarterly Market Summary & Community Consensus Trade Alerts - newser.com
Corcept Therapeutics (CORT) Rating Reiterated as 'Buy' by HC Wai - GuruFocus
Volume spikes in Corcept Therapeutics Incorporated stock – what they meanJuly 2025 Short Interest & Weekly Breakout Opportunity Watchlist - newser.com
Corcept Therapeutics' (CORT) "Hold (C)" Rating Reiterated at Weiss Ratings - MarketBeat
Insider Sell: William Guyer Sells 20,000 Shares of Corcept Thera - GuruFocus
Platinum-Resistant Ovarian Cancer Treatment Market Sees Momentum with Next-Generation Targeted Strategies | DelveInsight - The Malaysian Reserve
Corcept Therapeutics Incorporated stock trend outlook and recovery pathWeekly Profit Recap & Daily Volume Surge Signals - newser.com
Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 4.9%Here's Why - MarketBeat
Corcept Therapeutics Board Member Resigns, Continues as Consultant - MSN
Pre-ESMO insights: Corcept on platinum-resistant ovarian cancer - pharmaphorum
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT) and Genmab (GMAB) - The Globe and Mail
Corcept's NDA for its hypercortisolism treatment gets FDA nod - MSN
1 Cash-Heavy Stock with Exciting Potential and 2 That Underwhelm - The Globe and Mail
Myasthenia Gravis Pipeline Outlook Report 2025: Novel Therapeutics, Clinical Advancements, and Opportunities - The Globe and Mail
'This isn't a dress rehearsal': Why the coming months could be big for a Peninsula drug company that has survived decades - The Business Journals
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $135 - 富途牛牛
What Fibonacci levels say about Corcept Therapeutics Incorporated reboundWeekly Risk Report & AI Forecasted Entry and Exit Points - newser.com
Will Corcept Therapeutics Incorporated bounce back from current supportQuarterly Earnings Summary & Real-Time Volume Analysis - newser.com
Is a relief rally coming for Corcept Therapeutics Incorporated holdersJuly 2025 Weekly Recap & Free Safe Entry Trade Signal Reports - newser.com
QRG Capital Management Inc. Acquires 13,829 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Why Corcept Therapeutics Incorporated stock is seen as undervalued2025 Technical Overview & Real-Time Market Sentiment Alerts - newser.com
Visual analytics tools that track Corcept Therapeutics Incorporated performance2025 Bull vs Bear & Precise Swing Trade Entry Alerts - newser.com
Is Corcept Therapeutics Incorporated (HTD) stock undervalued by metricsJuly 2025 Short Interest & Low Risk Growth Stock Ideas - newser.com
Earnings Tell The Story For Corcept Therapeutics Incorporated (NASDAQ:CORT) As Its Stock Soars 27% - 富途牛牛
JSF Financial LLC Makes New Investment in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics (CORT): Evaluating Valuation After New Curant Health Partnership and Pipeline Progress - Yahoo Finance
Corcept Therapeutics (NASDAQ:CORT) Insider Joseph Douglas Lyon Sells 5,000 Shares - MarketBeat
Low-Volatility Stocks Underperforming: RSI, ADT, CORT AnalysisNews and Statistics - IndexBox
Here’s What Makes Corcept Therapeutics (CORT) an Attractive Investment? - Yahoo Finance
Synergy Asset Management LLC Raises Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Downgraded by Zacks Research to Strong Sell - MarketBeat
Public Employees Retirement System of Ohio Boosts Stock Holdings in Corcept Therapeutics Incorporated $CORT - Defense World
Will Corcept Therapeutics Incorporated (HTD) stock see insider accumulationJuly 2025 Update & Community Supported Trade Ideas - newser.com
Wealth Enhancement Advisory Services LLC Buys 5,693 Shares of Corcept Therapeutics Incorporated $CORT - Defense World
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Corcept Therapeutics Inc Stock (CORT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Guyer William | Chief Development Officer |
Oct 07 '25 |
Option Exercise |
21.65 |
20,000 |
433,000 |
25,287 |
| Guyer William | Chief Development Officer |
Oct 07 '25 |
Sale |
89.94 |
20,000 |
1,798,782 |
5,287 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):